|
|
 |
|
Viewing report
|
|
|
|
The Fastest Growing Biotechnology Companies: Growth Strategies, Comparative Analyses and Company Profiles
Business Insights, March 2008, Pages: 280
In recent years, the biopharmaceutical industry has emerged as one of the most important sectors in the Healthcare field. Advances in life sciences have resulted in the drug discovery process becoming more science-intensive, with an increasing emphasis on cross-company collaborations and the exchange of information.
However, growing commercial pressures and rising R&D costs have prompted many biotech companies to seek financial support from global Big Pharma corporations through licensing and collaborative R&D deals. Progressive enhancements in integration have subsequently led to traditional pharma companies becoming increasingly dependant upon the technology platforms and approaches adopted by biotech companies.
The Fastest Growing Biotechnology Companies: Growth strategies, comparative analyses and company profiles is a new report that examines the structure and organization of the biopharmaceutical industry with a detailed analysis of the fastest growing biotechnology companies.
This report provides a comparative analysis of growth strategies and reviews the methods used to improve operational efficiency in light of cost pressures, generic competition, complex pricing, regulations, and globalization. This report also explores the levels of interaction and integration between bio-pharma companies and the wider pharma industry.
Use key indicators to assess the performances of the fastest growing biotech companies, benchmark their most successful strategies and understand major industrial issues with this new report.
Top five reasons to order your copy today
- Identify the fastest growing biotech companies over the 2002-06 period, and use detailed company analysis to measure the performances and outlooks of major players including Theravance, ISTA, Palatin, Pharmion, Amylin, Trimeris, ViroPharma, NPS, SIGA and Idenix.
- Discover which therapeutic areas have been targeted by the fastest growing biotech companies and determine which strategies they have used to exploit proprietary technologies and intellectual property.
- Review the progress of biotech development programs and understand the regulatory status of new products in development, patents held and the current status of marketed products.
- Benchmark the strategies of the fastest growing biotech companies with this report’s assessment of the effectiveness and wider implications of a host of leading strategic implementations.
- Understand how bio-pharma drug discovery programs are being improved to develop more efficient methods in the screening of new chemical entities (NCEs).
Key issues examined in this report...
- Biotech losses. Only eleven of the world’s top twenty biotechnology companies currently attain a positive net income. This trend is a key industry-wide issue, with companies now attempting to stabilize financial performance.
- Developmental uncertainty. Bio therapeutic developments continue to face a high level of uncertainty. A wide array of factors can contribute to the delay or late-stage failure of promising products.
- External investment. Time-consuming, risky and expensive bio-pharma product developments require high levels of investment and investor patience, as market-generated revenues are often late in materializing. Investors often pursue milestone payments, joint ventures, out-licensing deals, or M&A as alternative exit strategies.
- Partnership trends. The majority of dedicated biotech companies have attempted to establish strategic alliances, joint ventures and even mergers between themselves and major pharma companies.
Some key findings from this report...
- Theravance, Inc. is the fastest growing biotechnology company in the world, with a growth rate of 12,456% over the 2002-06 period. However, Theravance also has one of the highest levels of net losses within the industry, highlighting the need to sustain more stable, predictable and stronger financial performance.
- ISTA Pharmaceuticals, Inc is the world’s second fastest growing biotechnology company, with a growth rate of 11,773% between 2002-06. Palatin Technologies, Inc. is in third position with a growth rate of 6,928% during the same period.
- Amylin Pharmaceuticals, Inc. recorded the greatest sales gains over 2002-2006, with an increase of $497.4mn during this period.
- The top 10 fastest growing biotechnology companies had a combined R&D expenditure of $734mn in 2006. This constitutes an increase of $324.7mn since 2002, and a five year growth rate of 179%.
- Flexible or adaptive clinical trial designs and proprietary Internet applications are helping to bring products to market faster by improving the efficiency of clinical trials. A prominent example of this is MetaTrial’s Electronic Data Capture (EDC) software.
Your questions answered...
- Who are the fastest growing biotechnology companies in the world?
- What is their level of R&D expenditure and how does this compare to their revenues?
- What proportion of biotech company revenues are accounted for by marketed products?
- What license agreements, joint ventures and partnerships have been established by the fastest growing biotech companies?
- How profitable is the biopharmaceutical industry?
- What key strategic tactics are being adopted by the fastest growing biotech companies in R&D, product commercialization, cost containment, manufacturing and screening/development of NCEs?
- What are the strengths, weaknesses, opportunities and threats to each of the companies profiled within this report?
- What is the product pipeline status of major biotech companies?
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Successful Pharmabiotech Alliance Strategies: Driving Synergies, Avoiding Failure and Managing Relationships
Biopharmaceuticals - A Global Market Overview
Biotech Investment and Business Trends: Weathering the Economic Storm
Who's Developing What in Global Biopharmaceuticals?
A Global Recession Drives New Business Strategies and Evolving Business Models in the Biopharma Industry
The CNS Market 2008 Report
Biotechnology - Global Outlook
Advances in Biopharmaceutical Technology in India
Building Biotech Technology Transfer Opportunities: Sponsor and Developer Strategies for Success
Multiple Myeloma Therapeutics - US Market Trends & Analysis
The Neurotechnology Industry 2010 Report
Delivering New Biopharmaceutical Therapies: Challenges & Opportunities
|
|
|
|
